Profile: ARCA Biopharma Inc (ABIO.OQ)
16 Aug 2019
ARCA biopharma, Inc. (ARCA), incorporated on March 16, 2004, is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors.
The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. GENETIC-AF is a multi-center, randomized, double-blind, adaptive design clinical trial comparing the safety and efficacy of Gencaro against an active comparator, the beta-blocker Toprol XL (metoprolol succinate). Its GENETIC-AF clinical trial of Gencaro requires a companion diagnostic test to identify the patient's receptor genotype.
ARCA Biopharma Inc
11080 Circle Point Rd Ste 140
WESTMINSTER CO 80020-2769